Kinarus Therapeutics Holding AG
KNRS | XSWX
Overview
Corporate Details
- ISIN(s):
- CH1330780979
- LEI:
- 506700VDL70GGMHR5758
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases. Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life. Recently, in response to the global challenge of COVID-19, Kinarus has initiated clinical evaluation of its combination therapy to treat patients suffering from SARS-CoV-2 infection. Kinarus has discovered that KIN001 has anti-viral activity against SARS-CoV-2, including against its variants of concern. KIN001 also possesses anti-inflammatory and anti-fibrotic activity.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-25 11:31 |
Declaration of Voting Results & Voting Rights Announcements
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 7.1 KB | |
| 2025-05-24 02:00 |
Declaration of Voting Results & Voting Rights Announcements
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 8.8 KB | |
| 2025-05-23 07:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 13.1 KB | |
| 2025-05-23 02:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 15.4 KB | |
| 2025-05-23 00:00 |
Investor Presentation
Investor Presentation
|
English | 958.3 KB | |
| 2025-05-02 00:00 |
Corporate Governance Report
Articles of Incorporation
|
English | 2.0 MB | |
| 2025-03-27 07:00 |
Regulatory News Service
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patient…
|
English | 20.6 KB | |
| 2025-03-27 01:00 |
Regulatory News Service
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patient…
|
English | 23.8 KB | |
| 2025-03-27 00:00 |
Investor Presentation
Investor Presentation
|
English | 1.1 MB | |
| 2025-03-27 00:00 |
Regulatory News Service
Annual Report 2024
|
English | 1.4 MB | |
| 2025-03-12 07:00 |
Board/Management Change
Curatis Announces Formation of Distinguished Advisory Board
|
English | 10.3 KB | |
| 2025-03-11 07:00 |
Board/Management Change
Curatis Announces Formation of Distinguished Advisory Board
|
English | 10.3 KB | |
| 2025-03-11 01:00 |
Regulatory News Service
Curatis Announces Formation of Distinguished Advisory Board
|
English | 12.1 KB | |
| 2024-11-14 01:00 |
Regulatory News Service
Curatis wird für C-PTBE-01 in den USA eine Biologic License beantragen - damit …
|
German | 11.8 KB | |
| 2024-09-16 02:00 |
Earnings Release
Curatis: Deutlich gesteigerter Umsatz im Kerngeschäft und Projekte in Entwicklu…
|
German | 26.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-25 | N/A | Non-Executive member | Buy | None | 1.11 CHF |
| 2023-10-31 | N/A | Executive member | Sell | None | 4,248.75 CHF |
| 2023-09-07 | N/A | Executive member | Sell | None | 11,713.02 CHF |
| 2023-06-23 | N/A | Executive member | Sell | None | 45,028.85 CHF |
| 2023-06-13 | N/A | Executive member | Sell | None | 38,761.94 CHF |
| 2023-06-05 | N/A | Executive member | Sell | None | 1,417,143.65 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 7,441,035.53 CHF |
| 2022-06-02 | N/A | Non-Executive member | Buy | None | 2,483,942.78 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 922,192.69 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 399,716.30 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |